RespireRx Pharmaceuticals Inc (RSPI)

[ombowstring]

His reply:

John, First, suggest you and other shareholders listen in on the presentation at the Bank of Montreal meeting in NYC on December 5, 2007 (we are on at 9 AM EST). However, I have already answered your question regarding the Psychiatric Division decision on CX717 for ADHD. While we will pursue avenues to determine if we can get a meeting with experts to discuss CX717 with that division, we are moving forward with the development of CX717 in acute respiratory depression. We do not believe that there is a high likelihood of any reversal of the Psychiatry Division decision for this compound. We obviously do not agree with the decision, but I would not count on having the decision reversed. We have plenty of other irons in the fire, and while we will continue to pursue a meeting with Psychiatry, in no way do we want our shareholders hanging on to that issue as an opportunity. Respiratory depression is very real and has a very strong mechanistic relationship among various species and we believe will have great likelihood of succeeding in humans as well. Also, we have potential back-up candidates which we will be pushing forward in ADHD because we already know that we can get a response in patients from our CX717 experience. Our objective is to develop a back-up which can succeed in ADHD. Also, we will continue to pursue Alzheimer’s disease which is also a promising area of therapy. We do not think that we will have to worry about our stock price being at this very low level later next year because we have several opportunities to show good progress with the AMPAKINE® technology and believe we can therefore improve our stock price. Roger